The Greater Boston Chapter of SoPE aims to serve as a catalyst for healthcare innovation by providing a platform and network to help physicians transform ideas into solutions for patients.
Dr. John Hallinan
Dr. Kiran Reddy
Dr. Omar Amirana
Five Top Reasons You Should Attend Greater Boston SoPE Chapter events
- 1. Learn by Example & perfect your own!
- 2. Understand what seasoned investors expect in real life terms
- 3. Networking with like-minded professionals
- 4. Create your own Due Diligence process
- 5. Be Part of It!
Dr. John Hallinan
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.
John's fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.
Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur's University.
Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company's healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies' CFO, he guided the company's first and second rounds of venture funding.
John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.
Rakhshita is the Innovation Services Manager at MassBio. She is in charge of managing Innovation Services programs including MassCONNECT and the Innovation Exchange.
Rakhshita earned her MS in Biotechnology from Georgetown University. Prior to MassBio she interned at Adjuvant Global Advisors, a life science business development firm in Bethesda, MD. She is passionate about life sciences and its interaction with the world of business and commercialization.
Kiran Reddy is a Senior Director in the Corporate Strategy / Capita group at Biogen Idec. Biogen is a global biopharmaceutical company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. At Biogen Idec, Kiran is focused on sourcing new technologies and product opportunities to support the Company's growth via acquisitions, partnerships, and equity investments. Prior to Biogen Idec, Kiran was an Associate Partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He was founder and interim Chief Business Officer for SAGE Therapeutics through its IPO. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Before Third Rock Ventures, Kiran was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy. Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard / Massachusetts General Hospital and is a board certified neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.
Omar Amirana, MD
Dr. Omar Amirana is Senior Vice President of Allied Minds (LSE:ALM), a publicly listed innovation commercialization firm. He manages the Allied Minds Life Sciences portfolio and currently serves as the CEO of three of its subsidiaries (SciFluor, LuxCath and Biotectix) as well as a board member for a number of its subsidiaries. Prior to Allied Minds, from 2005 to 2011, Omar was Partner at Oxford Bioscience Partners, a Boston-based venture capital firm with ~$1 billion under management. He has served on the boards of life science companies, including nFocus Neuromedical, Flowmedica, SmartPill, Coherex, Mitralign, and Cambridge Endoscopic Devices. Omar is currently on the board of Cardiofocus (AF catheter ablation) as well as the Ignition Awards Committee at Boston University. Prior to investing, he worked in the life sciences industry as Vice President of Business Development at St. Jude Medical (NYSE:STJ). He was a co-founder of Cardima, a cardiology catheter company in Silicon Valley which was funded by Kleiner, Perkins, Caufield and Byers, as well as New Enterprise Associates (NEA) and went public. He has developed and launched products worldwide. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.